{"id":16496,"date":"2020-07-22T11:14:32","date_gmt":"2020-07-22T15:14:32","guid":{"rendered":"https:\/\/medicarereport.org\/?p=16496"},"modified":"2020-07-22T11:14:32","modified_gmt":"2020-07-22T15:14:32","slug":"could-aducanumab-be-the-first-drug-to-slow-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=16496","title":{"rendered":"Could aducanumab be the first drug to slow Alzheimer&#8217;s disease?"},"content":{"rendered":"<p>The biotechnology company Biogen along with Japanese pharmaceutical company applied for a Biologics License Application with the U.S. Food and Drug Administration for regulatory approval of aducanumab. \u00a0Aducanumab is an investigational biologic medication for early Alzheimer\u2019s disease to slow the clinical progression of the disease.\u00a0 The FDA was given 60 days to decide whether the application was granted Priority Review status upon acceptance. Read article <a href=\"https:\/\/medtruth.com\/articles\/news\/first-drug-to-slow-alzheimers-submitted-for-fda-review\/\">here\u2026<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo3.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-7883\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo3.jpg\" alt=\"\" width=\"179\" height=\"181\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>The biotechnology company Biogen along with Japanese pharmaceutical company applied for a Biologics License Application with the U.S. Food and<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,31,15],"tags":[],"class_list":["post-16496","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-fda","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16496"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16496\/revisions"}],"predecessor-version":[{"id":16497,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16496\/revisions\/16497"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}